Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06050122 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
A Phase 3 study of Gorlin Syndrome, sponsored by Sol-Gel Technologies.
- Active
- Registry status
- Phase 3
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT06050122 is a Phase 3 study of Gorlin Syndrome that is active but no longer recruiting, run by Sol-Gel Technologies. The registered enrollment target is 140 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT06050122, a Phase 3 study of Gorlin Syndrome, is active but no longer recruiting, sponsored by Sol-Gel Technologies.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use. People who take part will apply either Patidegib Gel 2% or a Vehicle Gel (with no active drug substance) to their face twice a day for a year (12 months). The number of new BCCs on the face will be compared between those who used Patidegib Gel 2% or Vehicle Gel after 12 months.
Conditions Studied
Interventions
- DRUG Patidegib Topical Gel
- DRUG Patidegib Topical Gel with no active patidegib
Study Locations (20)
California
- Center for Dermatology Clinical Research - Fremont
- University of California Los Angeles (UCLA) - Center for Inflammatory Bowel Diseases - Westwood Location - Los Angeles
- The Dermatology Center of Newport - Newport Beach
- Stanford University - Lucille Packard's Children's Hospital - Redwood City
Ohio
- Apex Clinical Research Center - Canton
- Cleveland Clinic - Main Campus - Cleveland
- Apex Clinical Research Center - Mayfield Heights
Florida
- Dermatology Associates of Tallahassee - Tallahassee
- University of South Florida Health - Tampa
Arkansas
- Northwest Arkansas Clinical Trials Center - Rogers
Connecticut
- Yale University - New Haven
Illinois
- The University of Chicago Medicine - Chicago
Maryland
- The Johns Hopkins Hospital - Baltimore
Michigan
- University of Michigan Health - Michigan Medicine - University Hospital - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2024-03-17 |
| Est. Completion | 2026-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06050122
The ClinicalTrials.gov registry entry for NCT06050122 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sol-Gel Technologies, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gorlin Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Patidegib Topical Gel is the first listed.
NCT06050122 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Ohio, Florida.
Frequently Asked Questions
What is clinical trial NCT06050122 about?
NCT06050122 is a clinical study titled "Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome". The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use. People who take part will apply either Patidegib Gel 2% or a Vehicle Gel (with...
What is the current status of trial NCT06050122?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 140 participants. The study started on 2024-03-17. Estimated completion is 2026-08.
What conditions does trial NCT06050122 study?
This clinical trial studies the following conditions: Gorlin Syndrome.
What interventions are being tested in trial NCT06050122?
The interventions under investigation include: Patidegib Topical Gel (DRUG), Patidegib Topical Gel with no active patidegib (DRUG).
Who is sponsoring clinical trial NCT06050122?
This trial is sponsored by Sol-Gel Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06050122 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.